Provided by Tiger Trade Technology Pte. Ltd.

Acumen Pharmaceuticals, Inc.

3.10
+0.02500.81%
Post-market: 3.100.00000.00%19:59 EDT
Volume:300.71K
Turnover:932.01K
Market Cap:223.86M
PE:-1.89
High:3.17
Open:3.09
Low:3.04
Close:3.08
52wk High:3.60
52wk Low:1.21
Shares:72.21M
Float Shares:37.05M
Volume Ratio:0.60
T/O Rate:0.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6370
EPS(LYR):-2.0035
ROE:-120.50%
ROA:-45.77%
PB:3.91
PE(LYR):-1.55

Loading ...

Acumen Pharmaceuticals, Inc. FY Net Income USD -121.335 Million VS. Ibes Estimate USD -124.8 Million

THOMSON REUTERS
·
Mar 26

Acumen Pharmaceuticals Inc - Expects Topline Results for Altitude-Ad Phase 2 Study in Late 2026

THOMSON REUTERS
·
Mar 26

Acumen Pharmaceuticals Inc - Targets Ind Filing for Lead Ebd Clinical Candidate in Mid-2027

THOMSON REUTERS
·
Mar 26

Acumen Pharmaceuticals, Inc. FY Basic EPS USD -2

THOMSON REUTERS
·
Mar 26

Press Release: Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights

Dow Jones
·
Mar 26

U.S. Earnings Preview: Before Market Open March 26

Dow Jones
·
Mar 26

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 25

Acumen Pharmaceuticals Inc expected to post a loss of 45 cents a share - Earnings Preview

Reuters
·
Mar 24

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 23

Acumen Pharmaceuticals Inc. to report fourth-quarter and full-year financial results and host conference call

Reuters
·
Mar 20

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026

GlobeNewswire
·
Mar 20

Acumen announces new research findings at Alzheimer’s and Parkinson’s conference

TIPRANKS
·
Mar 17

Acumen presents Phase 1 INTERCEPT-AD biomarker results for sabirnetug at AD/PD 2026

Reuters
·
Mar 17

Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery™, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026

GlobeNewswire
·
Mar 17

Maintaining Buy on Acumen (ABOS): EBD-Enabled Alzheimer’s Pipeline, Extended Runway, and Discounted Valuation Ahead of ALTITUDE-AD Readout

TIPRANKS
·
Mar 17

Acumen Pharmaceuticals Is Maintained at Buy by BTIG

Dow Jones
·
Mar 17

Acumen price target raised to $8 from $7 at BTIG

TIPRANKS
·
Mar 17

BUZZ-U.S. STOCKS ON THE MOVE-Customers Bancorp, Forgent Power Solutions, Nvidia

Reuters
·
Mar 17

BUZZ-U.S. STOCKS ON THE MOVE-Dollar Tree, Micron, Customers Bancorp

Reuters
·
Mar 16

Acumen Raises Capital to Advance Enhanced Brain Delivery

TIPRANKS
·
Mar 16